anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: pharmacy. SUBSTANCE: method involves extraction of propolis with alcohol-containing solvent, treatment with vegetable oil at boiling at ratio = 1: (5-10). Alcohol is distilled off to its content in the end product 0.1-0.5% and extract is incapsulated into gelatin capsules. Vitamin A or its derivatives were added to the preparation before capsulation. Alcoholic-oily component interacts with gelatin wall and an inner gel layer is formed. Method ensures to increase the retention of biologically active substances by 10%. EFFECT: improved method of preparing, increased retention. 3 cl, 2 tbl
All consenting participants will be receive an intravenous infusion of Obinutuzumab (1000mg) + Atezolizumab (1200mg) q3/52 x 6 cycles (plus 1000mg Obinutuzumab on day 8 and 15 of cycle 1). Responding participants (PR or SD) who do not achieve a CR at the end of cycle 2 will receive involved site radiotherapy (4Gy, 2 fractions) between cycle 3 and 4. At the end of cycle 6 and completion of the induction phase, responding participants (CR/PR/SD) will receive maintenance phase Obinutuzumab (1000mg IV) q8/52 for up to 12 cycles.
Today the majority of patients with renal tumors is diagnosed with localized disease amenable to nephron-sparing surgery (NSS). Partial nephrectomy (PN) constitutes the reference standard treatment for small renal masses according to international guidelines. Open PN ist still the predominant apporach in Germany, but the use of minimally-invasive surgery has continously increased over the last decades. Specifically, robotic surgery is on the rise and may facilitate the adoption of a minimally-invasive PN approach even in more complex renal tumours. Real world data on the outcomes of PN according to the surgical approach are limited. Data from cancer registries and health insurance databases usually lack important information an key patient und tumour characteristics, such as tumour complexity.

The G-NESS registry database aims at prospectively collecting such clinical and outcome data from patients undergoing PN. Data collection includes perioperative variables on patient characteristics, tumour location and complexity, surgical approach, intra-/postoperative complications, and kidney function. Follow-up based on questionnaires is conducted after predefined intervals (i.e. 30 days, 12 months, 24 months, and 60 months) in order to receive information on long-term kidney function, comorbidities, and survival. The information received from the database can help to better define the optimal surgical care for patients with renal masses.
The natural history of a disease is how a disease progresses over time and impacts the lives of patients and their families. In Congenital Central Hypoventilation Syndrome (CCHS), as in all rare diseases, collecting enough information to understand disease natural history is challenging. Knowledge and data sharing is a key to overcoming this challenge. Investigators at Lurie Children's are collaborating with teams at other CCHS medical and research centers and patient advocacy groups to build a shared resource called the CCHS Secure Health-hub Advancing Research Efforts (CCHS SHARE). CCHS SHARE will advance knowledge of CCHS natural history and guide future research studies and clinical trials. The purpose of this study is to collect and store CCHS natural history data over the course of many years in CCHS SHARE. Collected information will include patient and family self-reports surrounding their health and its impact on daily life, information collected during standard clinical care (medical records), family history, and other related information from patients. Information in CCHS SHARE will be used for medical research to better understand CCHS and to develop new treatments.
Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
OBJECTIVES: Flavonoids exhibit antioxidative, anti-inflammatory, and anticancer properties, yet the relationship between flavonoid intake and all-cause mortality in the obese population remains unclear.
METHODS: This study included NHANES participants from 2007 to 2010 and 2017 to 2018. Cox regression analysis evaluated the impact of total flavonoid intake on all-cause mortality among participants with varying comorbidity profiles. Subgroup analysis was conducted by separately analyzing the six sub-classes of total flavonoids (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and isoflavones). Sensitivity analysis was used to investigate the impact of total flavonoid intake on all-cause mortality among patients with different comorbidities.
RESULTS: During a median follow-up period of 9.92 years (interquartile range (IQR), 5.54-14.29 years), a total of 639 participants died. COX regression analysis revealed a positive impact of flavonoid intake on all-cause mortality among participants with chronic kidney disease, with greater benefits observed in obese participants [hazard ratio (HR): 0.22, 95% CI: 0.11-0.44). In metabolically healthy obese participants (HR: 0.15, 95% CI: 0.07-0.35), obese individuals with diabetes (HR: 0.51, 95% CI: 0.29-0.88), and obese individuals with comorbid cardiovascular disease (HR: 0.37, 95% CI: 0.17-0.83), flavonoid intake was associated with a reduced risk of all-cause mortality. Restricted cubic spline (RCS) analysis indicated a non-linear relationship in obese participants, with optimal intake levels ranging from 319.4978 to 448.6907 mg/day, varying based on different comorbidity profiles. Subgroup analysis revealed varying effects of total flavonoid components in different health conditions, with hazard ratios ranging from 0.06 for higher levels of flavonol to 0.59 for higher levels of anthocyanidins in the Cox model. Sensitivity analyses further indicated that individuals with obesity and comorbid diabetes or CKD see the greatest benefit from flavonoid intake.
CONCLUSIONS: The consumption of flavonoids may be associated with a decreased risk of all-cause mortality. Consumption of flavonoids is particularly beneficial for individuals with obesity and comorbidities.
Ibuprofen acid ODTs: 2x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
Participants receive placebo in session 1 and Aprepitant in session 2 of a psychological stressor presentation and receive placebo in session 1 and Aprepitant in session 2 of a physiological stressor presentation. Participants take Aprepitant (80 mg) or placebo tablets for 7 days prior to each session.
The problem to be solved by the present invention is to provide a monoclonal antibody against canine CD20 which is more excellent in effect than the existing antibodies. A monoclonal antibody or antibody fragment directed against canine CD20 is provided, comprising: a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO. 1 or an amino acid sequence in which one to a plurality of amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO. 1; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO. 2, or an amino acid sequence in which one to a plurality of amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO. 2; and a light chain constant region comprising the amino acid sequence represented by SEQ ID NO. 3, or an amino acid sequence in which one to a plurality of amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO. 3.
Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Social Anxiety Disorder is recognized as a prevalent, chronic and disabling condition (Schneier et al, 1992). Lifetime prevalence has been estimated at 13% in the National Comorbidity Survey (NCS (Magee et al, 1996)). The age of onset of Social Anxiety Disorder (SAD) is early, usually in the teenage years, and social, academic and vocational impairment are often severe (Schneier et al, 1992; Stein et al, 2000). Depression and alcohol abuse are common sequelae.

There is a need for more therapeutic agents for Social Anxiety Disorder. At this time, only Paxil (paroxetine), Zoloft (sertraline), Luvox CR (fluvoxamine maleate), and Effexor XR (venlafaxine) are approved. However, each of these agents helps only about 45-55% of a given sample. Furthermore, the majority of those considered responders after an acute trial are still clinically symptomatic. The same can be said for the most effective form of psychosocial treatment for social anxiety disorder, Cognitive Behavior Therapy (CBT) (Heimberg et al, 1998), and other effective drug treatments such as phenelzine (Liebowitz et al, 1992) and clonazepam (Davidson et al, 1993). In addition, all of the drug treatments found effective to date have troubling adverse effects such as weight gain, sexual dysfunction, physical dependency, or inducing tolerance that can make long term use difficult. Thus, additional treatments are needed for Social Anxiety Disorder.

Vraylar® should be helpful for patients with SAD. It is a partial agonist at D2 and D3 receptors with affinity as well for a variety of serotonin receptors including 5-HT1A, 5-HT 2A 5-HT 2C and 5-HT 7. While it has been most extensively studied for its antipsychotic and anti-manic properties, its serotonergic and dopaminergic receptor profile suggests it may also be helpful for anxiety states. Social Anxiety Disorder is an excellent area to assess a medication's anti-anxiety properties. The disorder's high prevalence makes study enrollment fairly straightforward. Its chronicity mitigates against placebo response, which has been in the 30% range in most placebo-controlled trials. The most commonly used rating instrument for SAD, the Liebowitz Social Anxiety Scale (LSAS), has demonstrated validity and reliability. Most striking is the consistency and reproducibility of results from one trial to the next with the same agent. Registration trials for Zoloft® were 2 for 2 positive, for Paxil® 3 for 3, and for Effexor® XR 5 for 5. Finally, medications found effective for SAD have also been shown to work in generalized anxiety disorder, suggesting SAD as a good indication for proof of concept studies to test a medication's antianxiety properties.
OBJECTIVES: Vitamin D deficiency is common in pediatric chronic liver disease despite oral replacement. We evaluated vitamin D deficiency before and after liver transplant and the relationship between posttransplant and pretransplant vitamin D deficiency and graft rejection.
MATERIALS AND METHODS: Pediatric recipients with chronic liver disease (N =138) were divided into 4 groups: cholestatic liver diseases, cirrhosis, metabolic disorders, and acute liver failure. Pretransplant and posttransplant vitamin D levels, liver function tests, Pediatric End-Stage Liver Disease scores, rejection activity index scores by graft liver biopsy, and posttransplant patient survival were recorded.
RESULTS: There were 62 (45%) female and 76 (55%) male participants (mean transplant age, 6.1 ± 5.6 years). Pretransplant mean available vitamin D of 90 patients was 25.2 ± 20.9 ng/mL, with 36 (40%) within reference range. Posttransplant level for 109 patients was 27.3 ± 18 ng/mL, with 64 (58.7%) within reference range. Pretransplant and posttransplant levels were available for 61 patients, and mean pretransplant levels were lower than posttransplant levels (23.7 ± 19.3 vs 28.3 ± 16.9 ng/mL; P = .01). Patients with cholestatic liver disease had lower pretransplant vitamin D levels (P = .04), which disappeared after transplant. Pretransplant vitamin D levels were positively correlated with serum albumin levels (r = 0.20) in all patients and negatively correlated with total/direct bilirubin (r = 0.29 and r = -0.30) in those with liver diseases and cirrhosis. No correlations were found between pretransplant vitamin D levels and Pediatric End-Stage Liver Disease scores, rejection activity index scores, and posttransplant mortality.
CONCLUSIONS: Vitamin D deficiency is prevalent in pediatric chronic liver disease before and after transplant, especially for cholestatic liver diseases. However, no association between vitamin D levels and liver graft rejection or patient survival was noted. We recommend close monitoring and individualized vitamin D supplementation before and after liver transplant.
The production process is for a cow milk immunoglobulin prepn. contg. antibodies against Streptococcus mutans, and with dental caries-inhibiting effect. The prepn. is intended for oral admin., and the cows are immunised with Streptococcus mutans by intramuscular injection in order to promote the formation of the antibodies. Milk is collected from the cows when the level of antibodies in their serum reaches a max. value. The thus collected milk is used to form milk powder contg. antibodies and which is employed for the prodn. of the caries-inhibiting prepn.. This prepn. can be added to 1-5 equal parts of water to form a mouth wash to be used daily to inhibit the formation of Streptococcus mutans colonies on the tooth enamel. The product can also be added to a sugar-free sweet or other form of food, and 25 per cent or more of the immunoglobin can be worked into the food item. A further method of admn. is for the prepn. to be added to customary tooth powderor paste, the onset of Streptococcus mutans colonies, i.e. a complete single drink of milk produces an adequate contact between the teeth and immunoglobulin.
Information regarding overdose with LUMRYZ is derived largely from reports in the medical literature that describe symptoms and signs in individuals who have ingested GHB illicitly. In these circumstances, the co-ingestion of other drugs and alcohol was common and may have influenced the presentation and severity of clinical manifestations of overdose.

In adult clinical trials of immediate-release sodium oxybate, two cases of overdose with sodium oxybate were reported. In the first case, an estimated dose of 150 g, more than 15 times the maximum recommended dose, caused a patient to be unresponsive with brief periods of apnea and to be incontinent of urine and feces. This individual recovered without sequelae. In the second case, death was reported following a multiple drug overdose consisting of sodium oxybate and numerous other drugs.
Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
The present invention describes an extremely effective, simple, novel, inexpensive, safe and quick method to treat both acne and warts, each with a different etiology and different clinical symptoms, by topically applying an effective and safe amount of one or more polyvalent metal compounds. The present invention can also be used for prophylaxis of acne. The polyvalent metal compounds include, but are not limited to, bismuth compounds, zinc compounds, magnesium compounds, aluminum compounds, calcium compounds, copper compounds, titanium compounds, manganese compounds, chromium compounds, barium compounds, selenium compounds and iron compounds. The present invention can also be applied to the treatment of rosacea. The present invention can also be employed to prevent scarring and to facilitate healing or elimination of the scars once formed, and to be useful in depigmentation. The present invention can also be used for the prophylaxis and treatment of periodontitis and tooth mobility, as well as for promoting healthy growth of oral mucous membranes and tissues. ® KIPO & WIPO 2007
A novel 13-residue peptide Mo1659 has been isolated from the venom of a vermivorous cone snail, Conus monile. HPLC fractions of the venom extract yielded an intense UV absorbing fraction with a mass of 1659 Da. De novo sequencing using both matrix assisted laser desorption and ionization and electrospray MS/MS methods together with analysis of proteolytic fragments successfully yielded the amino acid sequence, FHGGSWYRFPWGY-NH2. This was further confirmed by comparison with the chemically synthesized peptide and by conventional Edman sequencing. Mo1659 has an unusual sequence with a preponderance of aromatic residues and the absence of apolar, aliphatic residues like Ala, Val, Leu, Ile. Mo1659 has no disulfide bridges distinguishing it from the conotoxins and bears no sequence similarity with any of the acyclic peptides isolated thus far from the venom of cone snails. Electrophysiological studies on the effect of Mo 1659 on measured currents in dorsal root ganglion neurons suggest that the peptide targets non-inactivating voltage dependent potassium channels.
Individuals in the treatment group will be invited to participate in CCA's IHSS Basic training program. The program is a 30 hour online course for IHSS providers, which teaches fundamental caregiving skills. Training includes personal care, infection control, nutrition and body mechanics, medication adherence, and home safety.
BACKGROUND: Critically ill patients in intensive care units (ICU) are frequently administered broad-spectrum antibiotics (e.g., carbapenems or piperacillin/tazobactam) for suspected or confirmed infections. This retrospective cohort study aimed to describe the use of carbapenems and piperacillin/tazobactam in two international, prospectively collected datasets.
METHODS: We conducted a post hoc analysis of data from the "Adjunctive Glucocorticoid Therapy in Patients with Septic Shock" (ADRENAL) trial (n = 3713) and the "Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure" (DIANA) study (n = 1488). The primary outcome was the proportion of patients receiving initial antibiotic treatment with carbapenems and piperacillin/tazobactam. Secondary outcomes included mortality, days alive and out of ICU and ICU length of stay at 28 days.
RESULTS: In the ADRENAL trial, carbapenems were used in 648 out of 3713 (17%), whereas piperacillin/tazobactam was used in 1804 out of 3713 (49%) participants. In the DIANA study, carbapenems were used in 380 out of 1480 (26%), while piperacillin/tazobactam was used in 433 out of 1488 (29%) participants. Mortality at 28 days was 23% for patients receiving carbapenems and 24% for those receiving piperacillin/tazobactam in ADRENAL and 23% and 19%, respectively, in DIANA. We noted variations in secondary outcomes; in DIANA, patients receiving carbapenems had a median of 13 days alive and out of ICU compared with 18 days among those receiving piperacillin/tazobactam. In ADRENAL, the median hospital length of stay was 27 days for patients receiving carbapenems and 21 days for those receiving piperacillin/tazobactam.
CONCLUSIONS: In this post hoc analysis of ICU patients with infections, we found widespread initial use of carbapenems and piperacillin/tazobactam in international ICUs, with the latter being more frequently used. Randomized clinical trials are needed to assess if the observed variations in outcomes may be drug-related effects or due to confounders.
Participants randomized to this arm will be invited to create a group that will attend monthly group medical visits at the rural health facility. Each group medical visit will be staffed by both the rural clinician and the local CHW (educator). Groups will consist of the same patients at each of 12 monthly visits. Each visit will begin with the measurement of fasting blood glucose and resting electronic BP, as well as the ascertainment of medication regimens for BP and diabetes, and extent of adherence to the prescribed regimen.
American Society of Anesthesiologists (ASA) class I and II patients aged 2-10 years who are scheduled for any elective surgery under general anesthesia will be enrolled. Patients in midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room, while 3 cc normal saline will be administered to control group patients. Difficulty of mask ventilation during induction of general anesthesia will be evaluated with the Han Mask Scale. Muscle relaxants will be given for intubation after evaluation. The anxiety and sedation level of patients will be estimated one minute before the intervention and one minute before anesthetic induction in an operating room.

Interventıon descriptıon Patients enrolled in this study are randomly allocated to midazolam group or control group. Total 120 patients will be enrolled. Each group consists of 60 patients. Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's mask scale.
Metformin is known to be substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive metformin. In patients with advanced age, metformin should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function. In elderly patients, particularly those ≥ 80 years of age, renal function should be monitored regularly and, generally, metformin should not be titrated to the maximum dose (see WARNINGS and DOSAGE AND ADMINISTRATION). 

Before initiation of metformin therapy and at least annually thereafter, renal function should be assessed and verified as normal. In patients in whom development of renal dysfunction is anticipated, renal function should be assessed more frequently and metformin discontinued if evidence of renal impairment is present.
Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 20 g/day Cornelian Cherry powder for their one portion fruit a day.
The present disclosure provides a functional rock or a rock powder thereof, and the use of the functional rock or a rock powder thereof. In one embodiment, the present disclosure provides a powder of the functional rock having a nanoscale particle size, and a production method for the functional rock powder. In one embodiment, the present disclosure provides hygiene products, clothes, cosmetics, sebum inhibitors, medicinal products, and quasi-drugs to which the functional rock or a rock powder thereof is added. These hygiene products, clothes, cosmetics, sebum inhibitors, medicinal products, and quasi-drugs, may exhibit a microorganism inhibition effect, an anti-oxidation effect, a blood circulation promotion effect, and/or a body temperature-increasing and maintaining effect. In one embodiment, the functional rock is a volcanic rock. In one embodiment, the functional rock is rhyolite.